Podcasts about myeloma

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.

Timestamps:      00:00- Introduction  00:41- Health benefits of yoga and mindfulness   02:34- The potential of AI in hematology  04:23- Transfusion dependence in myelodysplastic syndromes  08:13- The fascinating field of apheresis  10:56- How to provide high-quality, affordable healthcare?  15:44- Regulatory T cells in hematologic malignancies  19:55- CAR T clinical trials: regulatory insights  22:57- EBMT initiatives  30:06- Latest breakthroughs in amyloidosis   34:50- Reducing patient fear through education 

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and... The post Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! appeared first on VJHemOnc.

In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

Tom & Callum joined by Mags chat to broadcasting legend Sandy Roberts about Myeloma, how dangerous and common it is, what to look out for and of course the Gather Round Brekky fundraiser they're hosting at the incredible Adelaide Convention Centre. Show your support and get tickets for the Gather Round Brekky here: https://myeloma.org.au/gather-round-breakfast The ONLY way to wake up in Adelaide is with your best brekkie mates Tom & Callum on Fresh 92.7 Keep up to date on our socials. Instagram - @fresh927 Facebook - Fresh 92.7See omnystudio.com/listener for privacy information.

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn

In this episode, we sit down with Dr. Cesar Rodriguez of Mount Sinai Hospital in New York, NY to discuss… The post Hope in Myeloma: The Road to Long-Term Survival first appeared on The Bloodline with LLS.

Please visit answersincme.com/BCK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myeloma discusses the latest data in anti-CD38 quadruplet regimens in newly diagnosed multiple myeloma. Upon completion of this activity, participants should be better able to: Identify the role of anti-CD38 monoclonal antibody (mAB)–based quadruplet regimens in the treatment landscape for newly diagnosed multiple myeloma (NDMM); Review the latest clinical data of anti-CD38 mAB-based quadruplet regimens for transplant-ineligible patients with NDMM; and Analyze evidence-based strategies for optimizing outcomes with anti-CD38 mAB-based quadruplet regimens in patients with transplant-ineligible NDMM.

Diagnosis and treatment of cancers such as leukaemia and myeloma poses unique challenges. In this episode of the Clinical Update podcast, MIMS Learning editor Pat Anderson talks to haemato-oncologist Dr Majid Kazmi about how GPs and specialists can work together to build on progress in this area.After listening to this podcast, healthcare professionals should be better able to:Understand the heterogeneity of haematological cancersAppreciate important differences in staging and treatment between haematological and other cancersRecall key pointers on symptoms, patient history, and presentation patterns that could suggest haematological cancersReflect on how outcomes for patients with haematological cancers have changed in the last 20 yearsMake best use of referral pathways for haematological cancersYou can access the website version of this podcast on MIMS Learning to make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.Useful linksResources from MIMS LearningChronic myeloid leukaemia: staging and managementSkin problems in haematological diseaseAbnormal full blood count - red flagsMIMS Learning LiveMIMS LearningRegister for a free healthcare professional account Hosted on Acast. See acast.com/privacy for more information.

Returning to the show, Drs. Vincent Rajkumar and Aaron Goodman engage in a dynamic debate over the evolving landscape of smoldering multiple myeloma, focusing on the highly anticipated study recently co-authored by Dr. Rajkumar and published in The New England Journal of Medicine after being presented at ASH 2024. They dissect the study's findings, which highlight the impact of early intervention with daratumumab in delaying disease progression for patients classified as high-risk. The discussion explores the nuances of smoldering myeloma classification, the controversy surrounding risk stratification, and the historical context of prior studies that failed to change clinical practice. With their expert insights, Drs. Rajkumar and Goodman break down the implications of this research, questioning whether it truly shifts the standard of care and what it means for future treatment approaches. View the NEJM publication. https://www.nejm.org/doi/abs/10.1056/NEJMoa2409029 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

This week, Jonathan is joined by Fredrik Schjesvold, Head of the Oslo Myeloma Center Oslo University Hospital, Head of the Norwegian myeloma association, and President of the Nordic Myeloma Study Group.   Timestamps:      (00:00)-Introduction   (04:24)-Research into melflufen  (07:14)- Ide-cel CAR T-cell therapy  (09:40)-Predictors of overall survival  (12:15)-Innovative therapies for refractory myeloma  (14:04)-Bi-specific antibodies  (16:42)-Global guidelines for myeloma  (22:00)-Healthcare economics  (25:45)-Antibody-based therapies  (29:38)- Latest research into amyloidosis  (34:23)-Recent breakthroughs in myeloma  (38:06)-Fredrik's three wishes for healthcare     

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. And it most commonly impacts older adults, with higher prevalence among men and African Americans. What are the symptoms and signs that are often subtle or overlooked, leading to delays in diagnosis? What treatment options are available for those diagnosed? In this episode spoke with Jens Hillengass, MD, PhD, chief of the Myeloma and Amyloidosis Service and vice chair of research of the Department of Medicine at Roswell Park Cancer Institute about the importance of early detection, healthy lifestyle strategies, and recent advances in research that offer hope. We then sat down with Jacqueline Henry, BSN, RN, nurse manager for the lymphoma and myeloma department at Roswell Park, about what quality of life looks like for patients, treatment goals, and how to find hope after diagnosis.

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 appeared first on VJHemOnc.

This week, Jonathan is joined by Anna Sureda, Head of the Clinical Hematology Department at Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain, and President of the European Society for Blood and Marrow Transplantation (EBMT) Association, to discuss the latest in lymphoma therapies and stem cell transplantation. Timestamps:     (00:00)-Introduction  (01:48)-Memorable travels  (07:44)-Sureda's journey into hematology   (12:40)-Breakthroughs in lymphoma treatment   (17:54)-Advances in stem cell transplantation   (20:26)-EBMT initiatives  (29:17)-Allogeneic transplantation for T cell lymphomas  (34:32)-Challenges in treatment accessibility   (41:35)-How can we ensure health equity?  (46:00)-Advice to young hematologists   (47:40)-Sureda's three wishes for healthcare 

CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/maximizing-myeloma-outcomes-with-gprc5d-directed-therapy-practical-expert-case-studies-and-best-practices/29812/ This 15-minute audio podcast uses real-world patient cases to illustrate effective strategies for managing adverse events (AEs) associated with GPRC5D-directed therapies in multiple myeloma. Expert faculty discuss how to safely implement these therapies to achieve deep, durable responses while optimizing patient tolerability and quality of life. Listeners will gain insights into specific prophylaxis, dosing, and interprofessional management protocols to address unique AEs such as cytokine release syndrome, skin toxicity, and dysgeusia. This practical case-based discussion will equip healthcare professionals with actionable tools to improve outcomes for their patients with relapsed/refractory multiple myeloma. =

This week, Jonathan is joined by Marc Hoffman, Associate Professor in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, to discuss novel therapies for B-cell malignancies and current challenges in hemato-oncology.   Timestamps:     (00:00)-Introduction  (03:24)-What is molecular biophysics?  (07:01)-Marc's journey into hemato-oncology  (09:36)-Advice to young doctors  (13:08)-Treatment advances in diffuse large B-cell lymphoma   (19:11)-BRUIN study: pirtobrutinib for B-cell malignancies   (26:15)-Challenges in CAR-T therapy implementation  (31:31)-A pharmaceutical perspective   (38:10)-Regulatory insights into clinical trials  (40:58)-New horizons in hemato-oncology  (44:26)-Marc's three wishes for healthcare 

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMMOverview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm. Read the abstract. Read the simultaneous publication at NEJM. 2. Anito-Cel: New BCMA CAR T Therapy Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T. Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns. Read the abstract.3. CARTITUDE-4 Update Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care. Read the abstract.4. ANDROMEDA OS Data in AL Amyloidosis Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis. Insights into cardiac responses and crossover impact. Read the abstract.5. OPTIMUM Trial in Ultra-High-Risk NDMMFive-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. Subgroup outcomes highlighting both challenges and exceptional results. Read the abstract6. GMMG-HD7 Trial PFS Update Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT. Discussion on the role of CD38 in maintenance therapy. Read the abstract Read the simultaneous publication at JCO7. Exciting New Drugs Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody. Expert insights into their efficacy and potential to reshape myeloma care. Read the abstract

Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHMM24).

On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.

In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

In this week's episode we'll learn about new explorations in extramedullary myeloma. Then, we'll hear about the role of ruxolitinib in children with acute GvHD. Finally: yapping about YAP1 as a new treatment target in immune thrombocytopenia. Featured Articles:Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaRuxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 studyYAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Dr. Dominic Brandy has journeyed through a cancer diagnosis and found the benefits of turning to a plant-based meal plan. He provides us with numerous research studies about how our body and gut microbiome interact with phytonutrients.Dr. Brandy talks about stress reduction, breathing, emotional & spiritual health and the relation to having healthy cells in our bodies.Dr. Dominic Brandy is the Founder of Natural Insights Into Cancer. He has been a practicing medical doctor for 42 years running a plastic surgery/medspa/anti-aging practice during that time. He has published 76 scientific articles and 9 textbook chapters in the medical literature; written many consumer articles; and given over 200 lectures at international medical meetings.Learn more at naturalinsightsintocancer.com, check out his book Beat Back Cancer Naturally, and follow Dr. Brandy on Instagram @cancerveggiedoc Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

CancerNetwork® spoke with James R. Berenson, MD, about the potential role that JAK inhibitors may play in the treatment of patients with multiple myeloma. The conversation focused on the rationale for researching this drug class as well as ongoing initiatives to assess the utility of agents like ruxolitinib (Jakafi) for this patient population. Berenson, founder, medical and scientific director, and president and chief executive officer of the Institute for Myeloma and Bone Cancer Research and private practitioner in West Hollywood, California, described the factors associated with the overexpression of JAK in the bone marrow, which may constitute a prime survival factor for multiple myeloma. This overexpression may affect the checkpoint inhibitor proteins in the body, resulting in resistance to standard anti-myeloma therapies such as immunomodulatory drugs.  Additionally, he mentioned a patient case that had involved a scenario in which JAK-mutated multiple myeloma progressed following prior treatment with lenalidomide (Revlimid). According to Berenson, the disease's resistance to lenalidomide was primarily associated with proteins driven by JAK; subsequent treatment involving JAK inhibition proved successful in restoring the efficacy of lenalidomide.  Based on a rationale to target JAK overactivity in the bone marrow and results from this patient case, Berenson and colleagues have focused on researching ruxolitinib as a therapeutic candidate for potentially improving outcomes in multiple myeloma via JAK inhibition. Findings from a phase 1 trial (NCT03110822), for example, have demonstrated that the efficacy and tolerability of ruxolitinib plus methylprednisolone can be extended with lenalidomide in those with multiple myeloma. Additionally, other ongoing trials aim to combine ruxolitinib with agents such as selinexor (Xpovio). “The question is, where will ruxolitinib sit in the sequencing of treatment of [patients with] multiple myeloma? Where will selinexor be?” Berenson stated. “At this point, there's certainly been low use of these drugs, especially ruxolitinib in multiple myeloma. We hope, with a more positive signal, these drugs will move further up in the algorithm of how you treat multiple myeloma.” Reference Berenson JR, Limon A, Rice S, et al. A phase I trial evaluating the addition of lenalidomide to patients with relapsed/refractory multiple myeloma progressing on ruxolitinib and methylprednisolone. Target Oncol. 2024;19(3):343-357. doi:10.1007/s11523-024-01049-w

Yelak Biru, President and CEO of the International Myeloma Foundation (IMF), joins the show to share his remarkable personal and professional journey. After immigrating to the US from Ethiopia, Yelak was diagnosed with multiple myeloma at the age of 26, setting him on an extraordinary path as both a survivor and a passionate advocate for myeloma patients. He discusses pivotal moments in his treatment, including seeking second opinions, utilizing groundbreaking therapies like CAR-T, and his ongoing decision to reject a transplant. Now leading the world's first and largest nonprofit dedicated to improving the lives of those impacted by multiple myeloma, Yelak shares his vision for expanding IMF's global outreach, advancing research, and empowering patients and caregivers worldwide. Learn more about the IMF. https://www.myeloma.org/ Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199 

Multiple Myeloma is the second most common form of blood cancer, and the Canadian Cancer Society estimates there were 3,900 new cases last year. Jasmine Way lost her dad, Monty Way to the disease in 2023. Now she's planning an event to raise awareness and money for myeloma research, as well as programs to support patients. The Multiple Myeloma March is happening in Corner Brook at the Majestic Lawn this Sunday.

Dr. Cutler received his MD from McGill University, Montreal, Canada. Hesubsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff. Dr. Cutler is a Director of the Adult Cell Transplantation Program, Director of ClinicalResearch for Stem Cell Transplantation and Director of the Stem Cell TransplantationSurvivorship Program. He also works as an Associate Professor of Medicine at Harvard Medical School.

In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles:EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma Does IPSS-R down-staging before transplantation improve the prognosis of patients with Myelodysplastic Neoplasms? Increased risk of venous thromboembolism [or VTE] in young and middle-aged individuals with hereditary angioedema: a family study

In this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson. Don't miss out on this informative discussion with one of the leading experts in the field. About Dr. Jens Hillengass Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute, Buffalo, NY. Previously, he was the head of the autologous stem cell transplant program and the deputy chief of the multiple myeloma section at the University Hospital of Heidelberg, Germany. He earned his medical degree, residency, and fellowship at Heidelberg University, and completed a research fellowship at the National Cancer Institute. Dr. Hillengass co-chairs the bone and imaging group of the International Myeloma Working Group and serves on the Multiple Myeloma guideline committee at the National Comprehensive Cancer Network. About Dr. Muhammad Salman Faisal Dr. Muhammad Salman Faisal is currently a fellow at Roswell Park Comprehensive Cancer Center, in his third year of training, with keen interest in myeloma, CAR-T and access to care.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode of the Life Science Success Podcast we are joined by Stephanie Oestreich, Managing Director of the Myeloma Investment Fund, who has an extensive background in life sciences, leadership, and a unique perspective as a semi-professional violinist.   Stephanie shares her extensive background in life sciences and leadership, and discusses her passion for finding cures and treatments for devastating diseases like multiple myeloma. She provides insight into the innovative work of the Myeloma Investment Fund, their mission, and the process of fostering and investing in breakthrough therapies. Stephanie also touches on her teaching role at MIT and her unique perspective as a semi-professional violinist, drawing parallels between her musical and professional experiences.   00:00 Introduction to the Podcast 00:32 Sponsor Message: D3 Digital Media Marketing 01:21 Meet Stephanie Asterik 01:54 Stephanie's Journey in Life Sciences 03:48 The Complexity of Multiple Myeloma 04:51 Investing in Innovation 08:42 The Role of the Myeloma Investment Fund 11:03 Stephanie's Background and Leadership Lessons 15:02 The Art of Playing the Violin 18:33 Leadership Insights from Music 22:07 Final Thoughts and Reflections 27:55 Conclusion and Farewell  

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:1.      Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL02.     EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/3.     Predictors of un-sustained MRD-negativity in multiple myeloma: a)     Secondary analysis of FORTE trial: https://pubmed.ncbi.nlm.nih.gov/38048557/b)     Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials: https://pubmed.ncbi.nlm.nih.gov/38048552/4.     Kinetics of MRD resurgence and subsequent relapse in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34807986/5.     MRD2STOP trial (MRD-guided maintenance discontinuation): https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.1066.     MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial): https://pubmed.ncbi.nlm.nih.gov/37506339/ 

In this episode we explore the transformative journey of our host, Will, who found solace and strength in the principles of manifestation during one of the most challenging times of his life. In this deeply personal and inspiring series, Will shares his story of how he discovered the concept of manifestation and the profound impact it had on his life. At a pivotal moment, facing a daunting diagnosis of multiple myeloma, Will turned to the book The Secret for guidance. This best-selling book, renowned for its teachings on the law of attraction, became a beacon of hope and a tool for change in Will's life. Through candid conversations and heartfelt reflections, Will discusses: The initial shock and emotional turmoil of being diagnosed with myeloma. His journey of discovering The Secret and how its teachings resonated with him. Practical techniques and exercises he implemented from the book that helped shift his mindset. Personal stories of triumph and moments of doubt, and how manifestation played a role in navigating through them. Insights into the law of attraction and how focusing on positive thoughts and intentions can lead to extraordinary outcomes. Whether you're a believer in the power of manifestation or just curious about its potential, Will's story will inspire and empower you to harness your own inner strength and embrace the possibilities of a positive mindset. Tune in to "Manifesting Miracles" and embark on a journey of hope, healing, and the incredible potential within us all. Enrolling for Soulful & Sober Purpose Blueprint: Are you at a point in your life you know you can't drink alcohol? You're feeling lost though. You know you don't want to turn to alcohol, but often feel like you're missing out. In this 6-week program, you'll learn tools to begin to not feel like alcohol is running the show, begin to find more purpose in your life, and heal now that you're focusing on your health. Contact me for more info or sign up here. Spots limited https://chrissyjaniga.thrivecart.com/soulfulsoberpurpose/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles:Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newlydiagnosed myelomaPlasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosisSickle cell disease iPSC-derived sensory neurons exhibit increased excitability and sensitization to patientplasma

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4:https://www.youtube.com/watch?v=VSjdGeeXb40

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope… The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with LLS.